Hi Castaway,
If you reference the latest investor presentation. (https://www.imugene.com/s/IMU-deck-May24.pdf).
Page 7 has the Azercel data / slides. This phase 1 trial was completed Precision Bio and is what IMU purchased.
84 patients dosed. If you back calculated the NHL and leukaemia groups; you end up with 39 Complete response and 58% overall response rate.
We haven't had any updates from IMU trial DLBL, which is the phase 1b expansion (I think 10 - 15 patients).
The MAST trial results released to date (Vaxinia / CF33). 1 CR, 2 PR, 17 SD from 40 screened patients, which can be referenced from the most recent Quartey update announcement.
Hi Castaway, If you reference the latest investor presentation....
-
- There are more pages in this discussion • 1,941 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |